期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
TREATMENT OF PATIENTS WITH MALIGNANT PLEURAL EFFUSIONS DUE TO ADVANCED LUNG CANCER BY TRANSFER OF AUTOLOGOUS LAK CELLS COMBINED WITH rIL-2 OR rIL-2 ALONE
1
作者 李殿俊 王跃荣 +3 位作者 姚晓东 邵杰 陈云富 巴德年 《Chinese Medical Sciences Journal》 CAS CSCD 1990年第1期51-55,共5页
Experimental study both in vitro and in vivotogether with clinical trials showed that LAKcells have antitumor and antimetastatic effects(1-5)and that these effects are closely related tothe number of LAK cells transfe... Experimental study both in vitro and in vivotogether with clinical trials showed that LAKcells have antitumor and antimetastatic effects(1-5)and that these effects are closely related tothe number of LAK cells transferred and the ad-ministration of rIL-2(1,6-8).Usually,autologousPBL’s are used as the source of LAK precursorsin the adoptive immunotherapy of cancer patients.But this not only puts an added burden on thecancer patient,it can cause serious side effectsas well(9).Although TIL’s may provide a solu-tion to this problem(10,11),their isolation fromsolid tumors is complex and consumes many rea-gents.We have reported that the isolation oflymphocytes from malignant ascites or from ma-lignant pleural effusions is not only simple 展开更多
关键词 PLEURAL EFFUSION lymphokine-activated KILLER cell(LAK cell) reconabinant interleukin-2(rIL-2) tumor in filtrating lymphocyte(TIL)
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部